The mRNA lipid Nanoparticle Competitive And Litigation Landscape

While the COVID-19 pandemic caused tragedy for millions of families worldwide, it has also spurred concomitant advancements in health care, not the least of which include the first-ever regulatory approvals of therapies based on messenger RNA (mRNA) technology granted to Moderna and BioNTech (in collaboration with Pfizer). At the dawn of this new era in therapeutics, companies operating in this space are eager to develop and commercialize new mRNA-based drugs but are also faced with the significant challenge of navigating an exceedingly complex IP, competitive, and litigation landscape. This webinar will provide a detailed survey of the current patent and patent litigation landscape for mRNA and lipid nanoparticle delivery technologies and provide analytical frameworks for companies that operate in this space to utilize when navigating these complicated issues.
Chapters of this Video
00:00 - Intro About the Speaker Daniel Shores, JD Partner Rothwell Figg
03:34 - Rothwell Figg mRNA/Lipid Nanoparticle Team
04:16 - mRNA a TimeLine
11:39 - Exemplary Areas of Innovation & Patentable Subject Matter
13:01 - Exemplary Areas of Patentability-LNP
20:07 - Patent Filing Trends
23:35 - Patent Filings By Assignee
24:36 - IP & Competitive Landscape
26:37 - Patent Litigation Landscape
51:38 - Technology At Issue
51:53 - Strategy: Freedom to Operate
52:14 - Strategy: Innovation and Protection
52:44 - Strategy: Licensing
53:17 - Strategy: IPR/PGR/Litigation
53:59 - Q&A and Closing